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1. Introduction 24 
Recently, a novel cell type, the so-called suburothelial myofibroblast (MF), has been 25 
identified in the lamina propria of the bladder wall. These cells form a functional 26 
syncytium through extensive connexin43 (Cx43) gap junction coupling. By their close 27 
proximity to afferent nerves and the fact that their own activity is modulated by 28 
exogenous agents, it is proposed that these cells act as modulators of afferent 29 
bladder sensation, and are able to integrate focal signals from different regions of the 30 
bladder wall[1], [2]. In this context, novel aspects have been added to existing 31 
concepts accounting for the pathogenesis of bladder overactivity (OAB): It has been 32 
proposed that changes in the sensitivity and coupling of the urothelial-myofibroblast  33 
network leads to an enhancement of spontaneous contractions . Modulating the 34 
coupling instensity between the cells would have an impact on signal propagation 35 
within the syncytium, and consequently the number of Ad –fibres stimulated [3]. 36 
The concept of gap junction remodeling is well established in cardiac research: 37 
Remodeling of Cx43 gap junction distribution and expression has been described in 38 
ischemia, infarction, and dilated cardiomyopathy [4-6] and is a potentially significant 39 
contributor to the arrhythmogenicity of cardiac disease [7-9]. Recent animal studies 40 
have provided increasing evidence that gap junctions play a role in the generation of 41 
unstable bladder condition: In a rat model of  detrusor overactivity (DO) induced by 42 
spinal cord transsection [3], a marked up-regulation of suburothelial gap junctions 43 
was demonstrated. Moreover, gap junction blockers were capable of reducing 44 
spontaneous bladder contractions. In contrast, in a preliminary study [10] of 7 45 
patients with urge symptoms, but no urodynamically confirmed DO, a trend towards 46 
increased suburothelial gap junction formation compared to normal controls failed to  47 
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reach statistical significance. A study with sufficient numbers of clinically well defined 48 
patients is lacking to date. 49 
Over the last 10 years, patients with intractable DO of neurogenic (NDO) or 50 
idiopathic (IDO) origin have been successfully treated with intradetrusor injections of 51 
BoNT/A. Placebo-controlled trials [11-14] have confirmed its impressive efficacy with 52 
symptomatic and urodynamic improvements [15, 16].  53 
It has been hypothesised that BoNT/A injected in the overactive human bladder has 54 
a complex inhibitory effect on urothelium/suburothelium dependant afferent 55 
pathways, which are important in mediation of intrinsic or spinal reflexes thought to 56 
cause DO [17]. Extending the hypothesis that the suburothelial myofibroblasts act as 57 
integrating stretch-receptor organ, an effect of BoNT/A on gap junctions in these 58 
cells might result in their reduced activation and electrical coupling. Mediation of 59 
afferent signalling between the urothelium and the closely apposed nerve endings 60 
would thus be reduced, achieving maximisation of the BoNT/A-induced peripheral 61 
desensitisation.  62 
We aimed to examine for the first time a possible role of suburothelial MFs in human 63 
neurogenic or idiopathic DO and whether the action of BoNT/A in human DO is partly 64 
exerted through an effect on suburothelial MFs. To do this, we studied the 65 
immunohistochemical expression of Cx43, vimentin and c-kit (markers of MFs) in 66 
patients with NDO/IDO before and after treatment with BoNT/A and in comparison 67 
with controls. 68 
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2. Methods 69 
 70 
2.1 Patients 71 
A total of 21 consecutive patients (17 women, 4 men, mean age ** years) from a 72 
group of patients with urodynamically proven refractory DO were treated according 73 
to a research protocol approved by the local Research Ethics Committee. 74 
Intradetrusor injections of BoNTA (Botox®, Allergan Ltd) were delivered by a 75 
minimally invasive outpatient technique using a flexible cystoscope [18]. Patients 76 
with NDO received 300 units of Botox®, while those with IDO received 200 units, 77 
injected at 30 and 20 sites respectively, avoiding the trigone [11]. 10 patients (8 78 
women, 2 men, mean age 48.2+-5.9 years, range 42 to 60) had NDO, 11 patients 79 
(10 women, 1 man, mean age 48.2+-15.9 years, range 19 to 68) had IDO. Flexible 80 
cystoscopic bladder biopsies were obtained at baseline pre-treatment, and during 81 
check flexible cystoscopy, 4 and 16 wk after each treatment session. Biopsies were 82 
obtained from a consistent bladder area, 2 cm above and lateral to the ureteric 83 
orifices [19]. Control tissue was obtained endoscopically from 10 patients (8 women, 84 
2 men, mean age 52.7±13.4 years, range 31 to 72) being examined under 85 
anesthesia prior to pelvic floor repair procedures, who had macroscopically normal 86 
bladders, no symptoms of bladder overactivity, and sterile urine at the time of 87 
endoscopy.  88 
 89 
2.2 Immunohistochemistry 90 
All histology biopsy specimens were snap-frozen in liquid nitrogen, embedded in 91 
optimal cutting temperature compound, and kept at -60°C, until frozen. 2 x 3 sections 92 
(10µm) per specimen were cut in a cryostat and collected on superfrost 93 
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aminopropyltriethoxysilane-coated slides. Sections were post-fixed in methanol at -94 
20°C for 5min, rinsed twice in PBS and blocked in 1% BSA for 45min before 95 
incubation with the primary antibodies for 2h at RT. For quantitative 96 
immunofluorecence, 3 sections per specimen were co-labelled for vimentin (rabbit 97 
polyclonal, Abcam, ab 7783-500; 1:100) and Cx43 (mouse monoclonal, Chemicon, 98 
MAB 3067; 1:1000), 3 further sections for c-kit (mouse monoclonal, NovoCastra, 99 
NCL-cKIT; 1:100) and Cx43 (rabbit polyclonal, Invitrogen, 71-0700; 1:500). For Cx45 100 
labelling (kind donation of Prof NJ Severs, Imperial College, London), sections were 101 
incubated over night at RT. Binding sites were visualised using Cy3- and FITC-102 
conjugated secondary antibodies (Cy3, goat anti mouse, Chemicon, AP181C; 1:500; 103 
FITC, donkey anti rabbit, Chemicon, AP182F; 1:50); nuclei were counterstained with 104 
DAPI (Invitrogen, D1306, 1:50.000) during incubation with one of the secondary 105 
antibodies. Slides were coverslipped using Citifluor Mounting medium (Agar 106 
Scientific), and immediately photographed. Immunolabelled sections were examined 107 
using a laser scanning microscope (Zeiss LSM-510 Meta, Germany) equipped with 108 
an argon laser (458nm, 488nm, 514nm), a helium-neon laser (543nm, 633nm) and a 109 
405 nm diode laser, using a x40 oil-immersion objective. Fluorescence was excited 110 
at 488nm (Cy3), 405nm (DAPI) and 543nm (FITC) and recorded with separate 111 
detectors. Multitrack scanning avoided ‘bleeding through’ of the fluorescence in 112 
doublelabelling experiments. 3 images per section (areas with highest 113 
immunoreactivity)  were taken in a blinded fashion, rendering 9 representative 114 
images of the suburothelial gap junction-network per biopsy for analysis. To ensure 115 
comparability of fluorescence signa l intensity between the samples as well as 116 
comparability between this and previous studies [3, 10], we first calibrated the 117 
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detection system on a reference section and re-used the parameter settings 118 
(pinhole, optical slice>1µm; detector gain)  for all images.  119 
 120 
2.3 Quantitave analysis and statistics. 121 
For examining the amount of Cx43 labelling, a square section of 75x75µm, 122 
representing the minimal extension of the Cx43 positive band in a transversally cut 123 
section, was cropped from the Cx43-positive area of each image and analysed using 124 
ImageJ software (http://rsb.info.nih.gov). Determination of gap junction density was 125 
preferred to an estimate of the extension of the Cx43 positive band, as it was 126 
impossible to regulate the cutting plane for each biopsy in order to obtain a strictly 127 
transversal section. Only the monoclonal mouse Cx43 antibody was used for 128 
quantification, as it showed a much more intense and reliable staining than the 129 
polyclonal rabbit antibody. Colours were split to render images for the Cx, nuclear, or 130 
smooth muscle labels alone (Fig2). The images were then converted into  black-and-131 
white bitmaps after constant setting of threshold levels , with gap junctions now being 132 
represented by single black particles which were automatically counted at set 133 
parameters. The number of particles was additionally expressed as a ratio of the 134 
number of nuclei to normalise for any variation in cellular component in different 135 
sections.  For the numerical determination of c-kit positive cells within the Cx43 136 
positive band, a slightly larger section (120x120µm) was cropped to obtain higher 137 
numbers and more accurate  results, given the sparse distribution of this cell type. 138 
Vimentin-labelling was not considered suitable for quantification, as it represented a 139 
rather diffuse, ill-defined staining, compared to Cx43 and c-kit. Quantitative data are 140 
shown as mean±SEM. Differences between data sets were tested with Student’s t-141 
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test (unpaired for baseline vs. control, paired for baseline vs. 4 weeks vs. 16 weeks); 142 
the null hypothesis was rejected when p<0.05. 143 
 144 
 9 
3. Results 145 
3.1 Localisation of immunolabelling 146 
A band of strongly vimentin positive cells  was seen immediately below the 147 
urothelium, lying in rows, with their cell bodies and long projections parallel to the 148 
basal lamina (Fig. 1a). Cx43 immunolabelling was extensively distributed in the 149 
suburothelial layer, coinciding with the layer of vimentin positive cells, and 150 
sometimes slightly offset towards the detrusor layer, possibly suggesting that gap 151 
junctions, located on the cell filaments, projected somewhat away from the 152 
urothelium. The boundary of the Cx43/vimentin positive band was more sharply 153 
defined on the urothelium-facing side than on the submucosal side where the 154 
labelling density tended to decrease progressively with depth. Cx45 immunolabelling 155 
was not detectable in the suburothelium. 156 
C-kit labelling showed a sharp cellular staining of outstretched, spindle-shaped or 157 
stellate cells, loosely scattered across the whole suburothelium, a proportion being 158 
located within the vimentin/Cx43 positive band (Fig. 1b). Direct contacts between c-159 
kit positive cells were only rarely observed, but regularly with a punctuate Cx43 160 
positive staining interposed (Fig. 1c). Interestingly, there was only poor co-161 
localisation of c-kit and vimentin, the latter being present in the distal processes of 162 
ckit positive cells (Fig. 1d). 163 
3.2 NDO vs. IDO vs. controls and effect of BoNTA 164 
There was a significant, two-fold upregulation of gap junction density in both IDO and 165 
NDO patients compared to controls (Fig. 3a). The same results were obtained, when 166 
the number of gap junctions was correlated to the nuclear count (controls vs. NDO: 167 
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0.8±0.09 vs. 1.7±0.2), discounting the possibility that results might be confounded by 168 
various levels of section integrity. However, there was no return to control values 4 169 
and 16 weeks after BoNTA injection in both groups. The sharp cellular c-kit labelling 170 
was equally suitable for quantitative analysis. Mast cells potentially express the c-kit 171 
receptor, but they were easily recognised by their large, round cell bodies and large, 172 
round nuclei and excluded from analysis. Further, co-labelling with Cx43 enabled us 173 
to reliably determine the number of c-kit positive cells within the Cx43 positive band.  174 
In contrast to gap junction density, there were no significant differences between 175 
controls and NDO or IDO groups, respectively, and no changes were detected after 176 
BoNTA treatment.  177 
No differences could be identified between NDO and IDO baselines for both c-kit and 178 
Cx43. 179 
 180 
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4. Discussion 181 
This is the first study, to the best of our knowledge, to examine the role of 182 
suburothelial MFs in the neurogenic or idiopathic overactive human bladder. Using 183 
immunofluorescence we have found increased presence of the gap junction protein 184 
Cx43 in the suburothelium of both patient populations in comparison with controls, 185 
suggesting that increased gap junction formation in the suburothelium could have a 186 
causative association with human DO.  187 
 188 
4.1 IR characterisation of MFs 189 
Suburothelial MFs have first been characterised by electron microscopy, mainly on 190 
the basis of a fibronexus, intracellular stress, elongated processes, abundant 191 
vimentin intermediate filaments, extensive smooth ER, dense bodies, and the 192 
presence of an interrupted basal lamina [1] [20]. The identification of human MFs by 193 
immunohistochemistry remains controversial. As yet, no diagnostic marker has been 194 
identified that is predictably expressed by all MFs, and by no other cell type. A 195 
previous combined EM and immunofluorescence study [21] found MFs to stain 196 
intensively for vimentin, but only poorly for c-kit and not at all for alpha-SMA. Because 197 
vimentin filaments are found in MFs and fibroblasts but not in SMCs, vimentin antibodies are a useful 198 
tool with which to distinguish between MF candidates and SMCs, although fibroblasts cannot be 199 
excluded.  The cells also expressed abundant label for the gap-junctional protein, 200 
Cx43, but were immunonegative for Cx40 and Cx45. The Cx43 immunofluorescence 201 
represented gap junctions between myofibroblasts, preferentially located on deeply 202 
penetrating branching processes, as was confirmed by the specificity of 203 
electronmicroscopic immunogold labelling . Alpha-SMA as a useful marker for cell 204 
definition has been ruled out also by others [20, 22], whereas c-kit has repeatedly 205 
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been used to identify myofibroblasts. C-kit is a proto-oncogene encoding the 206 
receptor tyrosine kinase. The ligand for kit (NCL-cKit) is stem cell factor. Kit 207 
signalling is important for the development and survival of structurally related 208 
interstitial cells in the gut. However, c-kit-expression might be down-regulated in the 209 
stable adult cell line. In the guinea-pig suburothelium, c-kit labelling reveals a 210 
network of interconnected stellate cells with many branches. There is an evident co-211 
localisation with vimentin, although many vimentin-positive cells - equally branched 212 
and interconnected – were kit negative [23]. In the suburothelium of the human 213 
bladder however, c-kit positive cells show a much more scattered and sporadic 214 
distribution [24, 25], making a possible network formation rather unlikely. No staining 215 
for vimentin was performed in these studies. 216 
 217 
Our labelling is in line with previous reports. Vimentin-positive cell bodies with typical 218 
processes form a layer immediately underneath the urothelium coinciding with a 219 
dense band of Cx43, sometimes slightly offset towards the detrusor layer, reflecting 220 
the fact that the gap junctions, which are located on the cell filaments, project 221 
somewhat away from the urothelium. C-kit positive cells show the characteristic 222 
outstretched, spindle-shaped cell bodies and are located within the band of vimentin- 223 
and Cx43-positive cells. However, this cell population seems too sparsely distributed 224 
to form a network, and direct contacts between single cells can be observed only 225 
occasionally (but usually with an interposed gap junction). Also, there is only poor 226 
co-localisation of c-kit and vimentin which at best is present in the very distal 227 
branches of c-kit positive cells. The discrepancy between c-kit and vimentin-labelling 228 
has always been a matter of controversy [21, 23]. Some argue that only a 229 
subpopulation of SM express c-kit. At the end of cell growth when such cells have 230 
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fully differentiated from mesenchymal cells they lose their reactivity to c-kit. However, 231 
that does not explain the weak staining for vimentin of c-kit positive cells. 232 
 233 
4.2 Increased gap junction coupling in OAB 234 
Several recent studies in animals and humans have suggested an involvement of 235 
MFs and/or interstitial cells in the generation of the OAB syndrome. In the human 236 
detrusor found c-kit positive cells on the boundaries of muscle bundles were 237 
significantly increased in specimen from patients with either IDO or NDO compared 238 
to controls[26]. In guinea-pigs with bladder overactivity induced by BOO, Kubota et 239 
al. [25] demonstrated an increased density of c-kit positive cells, and an altered, 240 
more wide-spread distribution of vimentin-positive cells in the suburothelial space 241 
when compared with controls. Several studies [27-29] have shown an overall 242 
increase of connexin43 transcript and protein in the overactive and/or obstructed rat 243 
bladder, however, without structural localisation. A rat model of OAB showed 244 
significantly higher suburothelial cx43 immunoreactivity, and gap junction blockade 245 
reduced spontaneity, and it was proposed that spontaneous activity in the bladder 246 
requires gap junction upregulation in lamina propria myofibroblasts [3]. A study of the 247 
human overactive detrusor [30] found up-regulated Cx43 mRNA and a denser Cx43 248 
staining pattern, however, localising these gap junctions to the cytoplasmatic 249 
membranes of smooth muscle cells. Similarly, Neuhaus et al. [10] showed 250 
significantly higher Cx43 expression in the detrusor muscle and a tendency to higher 251 
Cx43 expression in the suburothelial layer to be associated with idiopathic urge 252 
symptoms. However, the study population was heterogeneous, comprising patients 253 
with urge incontinence, mixed incontinence, and painful bladder syndrome with no 254 
reported urodynamical confirmation of DO. 255 
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The present study was performed with tissue from 8 controls and 21 patients with 256 
cystometrically confirmed, refractory, IDO and NDO. In consistence with the 257 
literature, we found the suburothelium to be immunopositive for Cx43, but 258 
immunonegative for Cx45. We found a significant increase of about twofold control in 259 
both IDO and NDO. Interestingly, this was not accompanied by increased numbers 260 
of c-kit positive cells, nor was there a return to normal values after BoTNA treatment.  261 
The strategic position of MFs directly beneath the urothelium suggests they are a link 262 
between urothelial signalling during bladder filling and afferent fibre stimulation. They 263 
elicit spontaneous electrical and intracellular Ca2+-responses and also respond to 264 
exogenous agents, such as ATP, and low pH-agents postulated to be transmitters of 265 
sensory responses in the bladder [31, 32]. Moreover, cell functions are augmented 266 
through physical interaction with their neighbours. Signals initiated in one  group of 267 
cells can be transmitted through considerable distances in the suburothelial layer [2].  268 
Modification of the coupling characteristics of the suburothelial syncytium may have 269 
profound impact on bladder sensation and, thus, play a role in the development of 270 
urgency and detrusor overactivity. Although BoNTA injected into the bladder wall has 271 
been known to reduce the pathological sensation of urgency and suppress DO, the 272 
density of suburothelial gap junctions does not seem to be altered by intradetrusoral 273 
BoNTA injections. Thus, the suppression of DO by BoNTA might not be exerted via a 274 
remodeling of the Cx43 gap junction distribution, at least in the suburothelium. It 275 
seems plausible that Cx43, as a structural surrogate, is not affected in its density by 276 
BoNTA treatment, although altered release of transmitters might indirectly influence 277 
gap junction function, even though the gap junction proteins may not be changed. It 278 
has been shown to decrease sensory P2X3 and TRPV1 receptors in suburothelial 279 
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nerve fibres [33], which might represent the structural surrogate mainly affected by 280 
BoNTA in the suburothelial space. 281 
 282 
4.3 Methodological considerations 283 
The authors are well aware of the general methodological restrictions of quantitative 284 
immunohistochemistry. It is widely agreed that statistical differences of 25 % or lower are to be 285 
interpreted with caution due to the restricted accuracy of the method. Furthermore, areal or fibre-like 286 
staining is problematical as different cutting planes or angles might result in different countings in the 287 
same specimen. For example, a single nerve might be depicted as a singular dot or as multiple fibre-288 
like structures depending on the course it takes in relation to the cutting plane. Finally, staining and 289 
analysis procedures have to be kept as standardised and automated as possible. We are quite 290 
confident that the present study reflects these considerations to the maximal possible extent. First, we 291 
restricted our analysis to clear punctuate staining, that is gap junctions with a diameter of 0.1 µm [10], 292 
or to c-kit positive cells that due to their scattered distribution were easy to count. Second, we applied 293 
the same protocols for tissue processing, staining and analysis throughout. It has been reported that 294 
MFs become increasingly numerous toward the bladder neck [24], so we took care that biopsies were 295 
constantly taken from the same area. The fact that the punch biopsies were obtained the same way 296 
as the BoTNA injection was applied, namely via flexible cystoscopy without anaesthesia, naturally 297 
restricted size (regularly less than 1 mm3) and quality of the biopsy; it would have been unethical to 298 
subject the patient to general anaesthesia and rigid cystoscopy just for the sake of research. Several 299 
studies already published [33, 34] have been carried out using these specimen, and it will, for the 300 
same reasons, be the only kind of tissue available for future research in this field. However, we were 301 
convinced that the level of tissue preservation was sufficient to serve our purposes. Imaging and 302 
analysis were blinded and fully automated with constant parameter settings throughout as has been 303 
done in previous studies. To ensure that the analysis was not confounded by any kind of squeezing or 304 
twisting of the punch biopsy, we additionally correlated the number of gap junctions to the nuclear 305 
count and obtained identical results.  306 
 307 
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Figure legends 402 
 403 
Fig 1. Cross section of bladder urothelium and lamina propria; A: green: vimentin, 404 
red: Cx43; B and C: red: c-kit; green: Cx43; D: red: c-kit, green: vimentin. Bar 20 405 
µm. 406 
 407 
Fig 2. Illustration of the quantification process of suburothelial Cx43 408 
immunofluorescence. 409 
 410 
Fig 3. Summary of the quantitative analysis of Cx43 (A: IDO, B: NDO) and c-kit (C: 411 
IDO, D: NDO) immunofluorescence in biopsies from controls and IDO and NDO 412 
patients pre and post BoNTA treatment (4 and 16 weeks); data given as mean±sem; 413 
* p<0.05, ** p<0.005. 414 
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